Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9550036 | IMPEL PHARMS | Nasal drug delivery device |
Sep, 2032
(8 years from now) | |
US10507295 | IMPEL PHARMS | Nasal drug delivery device |
Dec, 2032
(8 years from now) | |
US10940278 | IMPEL PHARMS | Nozzles for nasal drug delivery |
Jan, 2033
(8 years from now) | |
US9919117 | IMPEL PHARMS | Nozzles for nasal drug delivery |
Mar, 2033
(8 years from now) | |
US11266799 | IMPEL PHARMS | In-line nasal delivery device |
Nov, 2036
(12 years from now) | |
US11185497 | IMPEL PHARMS | Intranasal delivery of dihydroergotamine by precision olfactory device |
Jan, 2039
(14 years from now) |
Trudhesa is owned by Impel Pharms.
Trudhesa contains Dihydroergotamine Mesylate.
Trudhesa has a total of 6 drug patents out of which 0 drug patents have expired.
Trudhesa was authorised for market use on 02 September, 2021.
Trudhesa is available in spray, metered;nasal dosage forms.
Trudhesa can be used as nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura.
The generics of Trudhesa are possible to be released after 04 January, 2039.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 02, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL